相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
Charles Frost et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban
Donglu Zhang et al.
DRUG METABOLISM AND DISPOSITION (2013)
Investigating the Enteroenteric Recirculation of Apixaban, a Factor Xa Inhibitor: Administration of Activated Charcoal to Bile Duct-Cannulated Rats and Dogs Receiving an Intravenous Dose and Use of Drug Transporter Knockout Rats
Donglu Zhang et al.
DRUG METABOLISM AND DISPOSITION (2013)
Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy
Ammar Majeed et al.
THROMBOSIS RESEARCH (2012)
Indications for single-dose activated charcoal administration in acute overdose
Geoffrey K. Isbister et al.
CURRENT OPINION IN CRITICAL CARE (2011)
Tissue Distribution and Elimination of [14C]Apixaban in Rats
Lifei Wang et al.
DRUG METABOLISM AND DISPOSITION (2011)
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Recombinant Factor VIIa to Manage Major Bleeding from Newer Parenteral Anticoagulants
Kellie A. Vavra et al.
ANNALS OF PHARMACOTHERAPY (2010)
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
Michael Rud Lassen et al.
LANCET (2010)
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement.
Michael Rud Lassen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Nirmala Raghavan et al.
DRUG METABOLISM AND DISPOSITION (2009)
Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans
Donglu Zhang et al.
DRUG METABOLISM AND DISPOSITION (2009)
Recombinant factor VIIa for warfarin-associated intracranial bleeding
Can Ityas et al.
JOURNAL OF CLINICAL ANESTHESIA (2008)
Apixaban, an oral, direct and highly selective factor Xa inhibitor:: in vitro, antithrombotic and antihemostatic studies
P. C. Wong et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
H. Buller et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa
Donald J. P. Pinto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Pharmacokinetics of quetiapine in overdose and the effect of activated charcoal
G. K. Isbister et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
The population pharmacokinetics of citalopram after deliberate self-poisoning: A Bayesian approach
LE Friberg et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2005)
Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males
H Stass et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Risk factors for emesis after therapeutic use of activated charcoal in acutely poisoned children
KC Osterhoudt et al.
PEDIATRICS (2004)
How long after drug ingestion is activated charcoal still effective?
R Green et al.
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY (2001)
Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose
PJA Yeates et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
分享论文
